GPC3 and hepatocellular carcinoma: On the other hand, similar to codrituzumab, when the analysis was limited to GPC3-expressing HCC, the recurrence rate in the first treatment + vaccination group was significantly lower compared to that in the group of initial treatment only: 24% vs. 48%, p = 0.047 for one-year recurrence rates, and 52.4% vs. 61.9%, p = 0.387 for two-year recurrence rates) [72].